vs
Side-by-side financial comparison of HeartSciences Inc. (HSCS) and ImageneBio, Inc. (IMA). Click either name above to swap in a different company.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of precision oncology therapies and targeted radiopharmaceuticals for hard-to-treat cancers. It primarily serves the North American healthcare market, with a core focus on advancing personalized treatment options matched to patients’ unique genomic profiles.
HSCS vs IMA — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4K | $0 |
| Net Profit | $-2.4M | $-24.8M |
| Gross Margin | 58.3% | — |
| Operating Margin | -85713.2% | — |
| Net Margin | -97179.4% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -12.9% | -678.5% |
| EPS (diluted) | $-0.85 | $-2.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.4K | — | ||
| Q3 25 | $1.9K | $0 | ||
| Q1 25 | $0 | $800.0K | ||
| Q3 24 | — | $3.5M | ||
| Q1 24 | $14.7K | — | ||
| Q4 23 | $3.9K | $658.0K | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | $0 | $2.0M |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | $-2.1M | $-24.8M | ||
| Q1 25 | $-2.5M | $-6.1M | ||
| Q3 24 | — | $-3.2M | ||
| Q1 24 | $-1.6M | — | ||
| Q4 23 | $-1.7M | — | ||
| Q3 23 | — | $-17.3M | ||
| Q2 23 | $-1.6M | $-17.1M |
| Q4 25 | 58.3% | — | ||
| Q3 25 | 60.0% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 69.0% | — | ||
| Q4 23 | 61.0% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -85713.2% | — | ||
| Q3 25 | -98637.8% | — | ||
| Q1 25 | — | -1349.3% | ||
| Q3 24 | — | -58.2% | ||
| Q1 24 | -10376.7% | — | ||
| Q4 23 | -40254.9% | — | ||
| Q3 23 | — | -1645.8% | ||
| Q2 23 | — | -922.7% |
| Q4 25 | -97179.4% | — | ||
| Q3 25 | -108157.6% | — | ||
| Q1 25 | — | -759.6% | ||
| Q3 24 | — | -90.9% | ||
| Q1 24 | -11182.4% | — | ||
| Q4 23 | -44830.2% | — | ||
| Q3 23 | — | -1463.5% | ||
| Q2 23 | — | -854.0% |
| Q4 25 | $-0.85 | — | ||
| Q3 25 | $-1.58 | $-2.91 | ||
| Q1 25 | $-2.57 | $-0.18 | ||
| Q3 24 | — | $-2.58 | ||
| Q1 24 | $-3.01 | — | ||
| Q4 23 | $-15.92 | — | ||
| Q3 23 | — | $-0.40 | ||
| Q2 23 | $-79.34 | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0M | $142.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $139.8M |
| Total Assets | $6.0M | $160.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $2.8M | $142.6M | ||
| Q1 25 | $2.6M | $114.1M | ||
| Q3 24 | — | $138.0M | ||
| Q1 24 | $7.1M | — | ||
| Q4 23 | $100.1K | $175.5M | ||
| Q3 23 | — | $196.9M | ||
| Q2 23 | $1.7M | $157.3M |
| Q4 25 | $4.2M | — | ||
| Q3 25 | $3.1M | $139.8M | ||
| Q1 25 | $1.8M | $-169.6M | ||
| Q3 24 | — | $-152.8M | ||
| Q1 24 | $8.6M | — | ||
| Q4 23 | $-1.6M | $-126.1M | ||
| Q3 23 | — | $155.3M | ||
| Q2 23 | $230.6K | $156.7M |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $6.4M | $160.9M | ||
| Q1 25 | $5.7M | $130.8M | ||
| Q3 24 | — | $149.0M | ||
| Q1 24 | $10.8M | — | ||
| Q4 23 | $2.4M | $192.1M | ||
| Q3 23 | — | $215.3M | ||
| Q2 23 | $3.3M | $171.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-26.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.3M | — | ||
| Q3 25 | $-2.0M | $-26.6M | ||
| Q1 25 | $-1.6M | $-10.6M | ||
| Q3 24 | — | $13.0M | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-988.2K | $-79.7M | ||
| Q3 23 | — | $-20.0M | ||
| Q2 23 | $-1.9M | $-18.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-990.1K | $-80.2M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-1.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -14352.1% | — | ||
| Q4 23 | -25388.2% | -12181.9% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 59.8% | — | ||
| Q4 23 | 50.1% | 62.9% | ||
| Q3 23 | — | 0.0% | ||
| Q2 23 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
